Posted by Michael Wonder on 09 Jan 2026
Wockhardt files marketing authorisation application for WCK 5222 with EMA
7 January 2026 - Wockhardt has successfully filed a marketing authorisation application with the EMA for its novel antibiotic, WCK 5222, on 5 January 2026.
Earlier, the EMA had informed Wockhardt that WCK 5222, a fixed dose combination of zidebactam (1 g) and cefepime (2 g), is eligible for accelerated assessment.
